NCCN VERSION 2 2015

162 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-87
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
278. Castiglione-Gertsch M, O'Neill A, Price KN, et al. Adjuvant
chemotherapy followed by goserelin versus either modality alone for
premenopausal lymph node-negative breast cancer: a randomized trial.
J Natl Cancer Inst 2003;95:1833-1846. Available at:
.
279. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant
epirubicin-based and docetaxel chemotherapy for node-positive breast
cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol
2006;24:5664-5671. Available at:
.
280. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide,
methotrexate, and fluorouracil versus tamoxifen plus ovarian
suppression as adjuvant treatment of estrogen receptor-positive pre-
/perimenopausal breast cancer patients: results of the Italian Breast
Cancer Adjuvant Study Group 02 randomized trial.
. J Clin Oncol 2000;18:2718-2727.
Available at: .
281. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety
of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment
(Intergroup Exemestane Study): a randomised controlled trial. Lancet
2007;369:559-570. Available at:
.
282. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in
postmenopausal women with early breast cancer after anastrozole
initiated after treatment with tamoxifen compared with continued
tamoxifen: the ARNO 95 Study. J Clin Oncol 2007;25:2664-2670.
Available at: .
283. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole
following tamoxifen as extended adjuvant therapy in receptor-positive
breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer
Inst 2005;97:1262-1271. Available at:
.
284. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and
tamoxifen as adjuvant treatment for early-stage breast cancer: 100-
month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53. Available
at:
285. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of
letrozole and tamoxifen in postmenopausal women with early breast
cancer. N Engl J Med 2005;353:2747-2757. Available at:
.
286. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in
combination with tamoxifen versus tamoxifen alone for adjuvant
treatment of postmenopausal women with early breast cancer: first
results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
Available at: .
287. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex,
Tamoxifen, Alone or in Combination) trial after completion of 5 years'
adjuvant treatment for breast cancer. Lancet 2005;365:60-62. Available
at:
288. Duffy S, Jackson TL, Lansdown M, et al. The ATAC ('Arimidex',
Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first
results of the endometrial sub-protocol following 2 years of treatment.
Hum Reprod 2006;21:545-553. Available at:
289. Fallowfield L, Cella D, Cuzick J, et al. Quality of life of
postmenopausal women in the Arimidex, Tamoxifen, Alone or in
Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol
2004;22:4261-4271. Available at:
.
290. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on
bone mineral density: 5-year results from the anastrozole, tamoxifen,
alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-
1057. Available at: